Onconephrology: The need and the emergence of a subspecialty in nephrology

Ala A. Abudayyeh; Amit Lahoti; Abdulla K. Salahudeen

doi:10.1038/ki.2014.29

Onconephrology: The need and the emergence of a subspecialty in nephrology

Ala A. Abudayyeh, Amit Lahoti, Abdulla K. Salahudeen

General Internal Medicine

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Original language	English (US)
Pages (from-to)	1002-1004
Number of pages	3
Journal	Kidney International
Volume	85
Issue number	5
DOIs	https://doi.org/10.1038/ki.2014.29
State	Published - May 2014

ASJC Scopus subject areas

Nephrology

Access to Document

10.1038/ki.2014.29

Cite this

@article{7cfed6d06cd2455b9a560c6feccfc2e4,

title = "Onconephrology: The need and the emergence of a subspecialty in nephrology",

author = "Abudayyeh, {Ala A.} and Amit Lahoti and Salahudeen, {Abdulla K.}",

note = "Funding Information: There are also several unaddressed research and clinical questions in onconephrology, and identifying onconephrology as a subspecialized field can help advance much-needed new research and guidelines in managing kidney disease in cancer patients. Some research areas are: (1) proactive approaches to prevent or minimize acute kidney injury (AKI) in cancer patients; (2) study of BK nephropathy in the SCT population, including new therapeutic trials; (3) further characterization of kidney disease of veno-occlusive disease and testing of therapeutic strategies to mitigate it; (4) evaluation of the significance of proteinuria and renal dysfunction as a unique presentation of graft-versus-host disease in SCT patients; (5) creation of a national renal toxicity database for older and newer chemotherapeutic agents; (6) use of pharmacokinetic data for dosing recommendations for chemotherapeutic agents in the chronic kidney disease (CKD) and end-stage renal disease (ESRD) populations and for the timing of dialysis; and (7) ongoing evaluation of kidney diseases related to myeloma and amyloid in the context of evolving oncological treatment—to mention a few areas. A brief Internet search revealed very little research funded by the US National Institutes of Health (NIH) or the National Cancer Institute in topics related to cancer nephrology. Under the Foundation for the NIH, a large multicenter study on AKI biomarkers in patients receiving potentially nephrotoxic drugs, including cisplatin in cancer patients, is currently under way. Clinical studies testing, for example, preconditioning strategies in hospitalized cancer patients who are at high risk for AKI are warranted. With the profusion of new cancer drugs, renal side effects have to be closely monitored and reported. Opportunities for nephrology research in cancer patients are plenty, and hopefully the onconephrology community will pursue such goals. ",

year = "2014",

month = may,

doi = "10.1038/ki.2014.29",

language = "English (US)",

volume = "85",

pages = "1002--1004",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Onconephrology

T2 - The need and the emergence of a subspecialty in nephrology

AU - Abudayyeh, Ala A.

AU - Lahoti, Amit

AU - Salahudeen, Abdulla K.

N1 - Funding Information: There are also several unaddressed research and clinical questions in onconephrology, and identifying onconephrology as a subspecialized field can help advance much-needed new research and guidelines in managing kidney disease in cancer patients. Some research areas are: (1) proactive approaches to prevent or minimize acute kidney injury (AKI) in cancer patients; (2) study of BK nephropathy in the SCT population, including new therapeutic trials; (3) further characterization of kidney disease of veno-occlusive disease and testing of therapeutic strategies to mitigate it; (4) evaluation of the significance of proteinuria and renal dysfunction as a unique presentation of graft-versus-host disease in SCT patients; (5) creation of a national renal toxicity database for older and newer chemotherapeutic agents; (6) use of pharmacokinetic data for dosing recommendations for chemotherapeutic agents in the chronic kidney disease (CKD) and end-stage renal disease (ESRD) populations and for the timing of dialysis; and (7) ongoing evaluation of kidney diseases related to myeloma and amyloid in the context of evolving oncological treatment—to mention a few areas. A brief Internet search revealed very little research funded by the US National Institutes of Health (NIH) or the National Cancer Institute in topics related to cancer nephrology. Under the Foundation for the NIH, a large multicenter study on AKI biomarkers in patients receiving potentially nephrotoxic drugs, including cisplatin in cancer patients, is currently under way. Clinical studies testing, for example, preconditioning strategies in hospitalized cancer patients who are at high risk for AKI are warranted. With the profusion of new cancer drugs, renal side effects have to be closely monitored and reported. Opportunities for nephrology research in cancer patients are plenty, and hopefully the onconephrology community will pursue such goals.

PY - 2014/5

Y1 - 2014/5

UR - http://www.scopus.com/inward/record.url?scp=84899767712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899767712&partnerID=8YFLogxK

U2 - 10.1038/ki.2014.29

DO - 10.1038/ki.2014.29

M3 - Article

C2 - 24786870

AN - SCOPUS:84899767712

SN - 0085-2538

VL - 85

SP - 1002

EP - 1004

JO - Kidney International

JF - Kidney International

IS - 5

ER -

Onconephrology: The need and the emergence of a subspecialty in nephrology

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this